Document is current
Any future updates will be listed below
-
Authors
Vetter, Marcus
Landin, Julia
Szczerba, Barbara Maria
Castro-Giner, Francesc
Gkountela, Sofia
Donato, Cinzia
Krol, Ilona
Scherrer, Ramona
Balmelli, Catharina
Malinovska, Alexandra
Zippelius, Alfred
Kurzeder, Christian
Heinzelmann-Schwarz, Viola
Weber, Walter Paul
Rochlitz, Christoph
Aceto, Nicola http://orcid.org/0000-0001-9579-6918
-
Funding
Funding for this research was provided by:
European Research Council
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Krebsliga Schweiz
Krebsliga Beider Basel
Eidgenössische Technische Hochschule Zürich
Universität Basel
- License Information
-
More Information
Article History
Received: 5 April 2018
Accepted: 23 October 2018
First Online: 20 November 2018
Ethics approval and consent to participate
: All study participants agreed and signed a written informed consent. The study was performed under the protocols EKNZ BASEC 2016-00067 and EK 321/10, which received ethical and institutional review board approvals before study initiation (Ethics Committee northwest/central Switzerland [EKNZ]). This study was performed in compliance with the Declaration of Helsinki.
: Not applicable.
: NA, BMS and FCG are listed as inventors in a patent application filed by the University of Basel, entitled “Inhibitors of bone resorption for treatment of metastasis” (#EP18161098). The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
